SOURCE: BioBalance Corporation

April 24, 2006 08:30 ET

BioBalance Announces Acceptance of Abstract to Be Presented at Major Scientific Meeting in Los Angeles

NEW YORK, NY -- (MARKET WIRE) -- April 24, 2006 -- BioBalance Corp. (BioBalance), a wholly owned subsidiary of New York Health Care, Inc.(OTC BB: BBAL), announced today the acceptance of a scientific abstract submitted for presentation at the Digestive Disease Week (DDW) conference to be held in Los Angeles, CA, May 20-25, 2006, at the Los Angeles Convention Center. The abstract highlights new scientific findings regarding Probactrix®, BioBalance's patented strain of the biotherapeutic agent E.coli M-17.

The abstract entitled, "Effects of the Probiotic E. Coli Strain M-17 on Chronic Dextran Sulfate Sodium-Induced Colitis in Mice" will be presented by Dr. Leo Fitzpatrick, Associate Professor in the Department of Surgery at Penn State College of Medicine. The full abstract is available online at the DDW web site and can be accessed at http://www.ddw.org by clicking on the "view accepted abstracts" link and searching for presentation number M1153.

This data will be presented at the DDW conference on May 22, 2006. The abstract will also be published in the April 2006 supplement to Gastroenterology, the leading peer-reviewed journal among GI specialists.

Digestive Disease Week (DDW) is the largest global medical conference in gastroenterology, hepatology, endoscopy and gastrointestinal surgery. The conference showcases approximately 5,000 abstracts of clinical studies and hundreds of lectures on the latest advances in GI research and treatments.

About BioBalance Corporation

BioBalance is a biopharmaceutical company focused on the development of innovative treatments for various GI disorders that are poorly addressed by current therapies via accelerated regulatory pathways. These disorders include pouchitis, Irritable Bowel Syndrome (IBS), Crohn's disease, ulcerative colitis, C. difficile infections and antibiotic-associated diarrhea. BioBalance's lead product, Probactrix®, recently received FDA approval to begin phase II clinical trials for pouchitis. Additional information on BioBalance is located on the BioBalance website at www.biobalance.com.

SAFE HARBOR STATEMENT: In addition to historical information, certain of the statements in the preceding paragraphs, particularly those anticipating future events, financial performance, business prospects and growth and operating strategies constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict, hope or similar expressions. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements, including, without limitation, satisfaction of regulatory and other approvals and conditions necessary to market Probactrix®, the Company's ability to implement its strategies and achieve its objectives and the risks and uncertainties described in reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation, the risk factors set forth and cautionary statements made in the Company's 2005 Annual Report on Form 10-K, its latest quarterly report on Form 10-Q and current reports on Form 8-K.

Consulting For Strategic Growth I, Ltd. ("CFSG1") provides The BioBalance Corporation with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement. Independent of CFSG1's receipt of cash compensation from BioBalance, CFSG1 may choose to purchase the common stock of New York Health Care, Inc. and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg.com.

Contact Information

  • CONTACTS:
    Simon Fischer
    Director of Corp. Development
    BioBalance Corp.
    Tel: (212) 679-7778
    Fax: (212) 679-7774
    Email Contact

    Stanley Wunderlich
    CEO
    Consulting For Strategic Growth
    Tel: (800) 625-2236
    Fax: (212)337-8089
    Email: Email Contact